1. Association between pioglitazone use and head and neck cancer: Population‐based case‐control study
- Author
-
Chuan Song Wu, Yi Wei Kao, Tzong Hann Yang, Herng Ching Lin, Ben Chang Shia, Sudha Xirasagar, and Yen-Fu Cheng
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Taiwan ,Logistic regression ,03 medical and health sciences ,0302 clinical medicine ,Diabetes mellitus ,Internal medicine ,Epidemiology ,medicine ,Humans ,Hypoglycemic Agents ,Pioglitazone ,business.industry ,Head and neck cancer ,Case-control study ,Cancer ,medicine.disease ,030104 developmental biology ,Otorhinolaryngology ,Head and Neck Neoplasms ,Case-Control Studies ,030220 oncology & carcinogenesis ,Propensity score matching ,business ,medicine.drug - Abstract
BACKGROUND This study aimed to evaluate the association between pioglitazone use and the occurrence of head and neck cancer. METHODS Data for this case-control study were retrieved from the Taiwan National Health Insurance Research Database. A total of 21 464 diabetic patients newly diagnosed with head and neck cancers were identified. We used propensity score matching to select 64 392 comparison patients (3:1 ratio). Multiple logistic regression modeling was used to examine the association of head and neck cancer with pioglitazone use in the 5 years preceding the cancer diagnosis. RESULTS Bivariate analysis showed a significant difference in the prevalence of prior using pioglitazone between cases and controls (19.3% vs 18.5%, P
- Published
- 2020